The FDA approved Lembaz for patients with early-onset Niemann-Pick disease type C after analysis found lower mortality and longer survival, though evidence came from 36 patients and external controls.
Lembaz Becomes First FDA-Approved Drug Shown to Extend Survival in Infantile-Onset Niemann-Pick Type C, Based on 36 Patients
by | Nov 19, 2026 | Uncategorized | 0 comments

Recent Comments